Drug Updates
As a service to our members, HOPA provides information about newly approved oncology drugs. Using the Food and Drug Administration (FDA) as our source, we routinely aggregate and share drug updates to help keep you informed and up-to-date.

Whether you are early in your oncology pharmacy career, or you have been practicing for awhile, knowledge is power. Take a look at the drug listings below and their corresponding pages at fda.gov - and be sure to watch for HOPA's Friday FDA Alert email, too!
Please note: In providing his information for members, HOPA does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described.
Pharmacist's Application to Practice (PAP)
HOPA's External Affairs Committee helps bring drug updates into focus by assigning, editing, and publishing a series of Pharmacist Applications to Practice, or PAPs.
PAP authors provide analysis and research on the application of these new drugs or indications and make their findings available as a resource for other members.
The Pharmacist Application to Practice page is currently under construction. Please check back soon for new PAPs.
-
Current as of: 05/04/2022Encorafenib (BRAFTOVI, Array BioPharma Inc.)
-
Current as of: 05/04/2022Ripretinib (QINLOCK, Deciphera Pharmaceuticals, LLC.)
-
Current as of: 05/04/2022Abatacept (ORENCIA, Bristol-Myers Squibb Company)
-
Current as of: 04/19/2023polatuzumab vedotin-piiq (Polivy, Genentech, Inc.)
-
Current as of: 04/17/2023omidubicel-onlv (Omisirge, Gamida Cell Ltd.)
-
Current as of: 04/03/2023enfortumab vedotin-ejfv (Padcev, Astellas Pharma)
-
Current as of: 03/22/2023retifanlimab-dlwr (Zynyz, Incyte Corporation)
-
Current as of: 03/16/2023dabrafenib (Tafinlar, Novartis)
-
Current as of: 03/03/2023abemaciclib (Verzenio,, Eli Lilly and Company)
-
Current as of: 02/09/2023dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC)
-
Current as of: 02/03/2023sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences, Inc.)
-
Current as of: 01/27/2023elacestrant (Orserdu, Stemline Therapeutics, Inc)
-
Current as of: 01/27/2023pirtobrutinib (Jaypirca,, Eli Lilly and Company)
-
Current as of: 01/26/2023pembrolizumab (Keytruda, Merck)
-
Current as of: 01/19/2023zanubrutinib (Brukinsa, BeiGene USA, Inc.)
-
Current as of: 01/19/2023tucatinib (Tukysa, Seagen Inc.)
-
Current as of: 12/22/2022mosunetuzumab-axgb (Lunsumio, Genentech, Inc)
-
Current as of: 12/16/2022nadofaragene firadenovec-vncg (Adstiladrin, Ferring Pharmaceuticals)
-
Current as of: 12/14/2022capecitabine (Xeloda, Genentech, Inc.)
-
Current as of: 12/12/2022adagrasib (Krazati, Mirati Therapeutics, Inc)
-
Current as of: 12/09/2022atezolizumab (Tecentriq, Genentech, Inc)
-
Current as of: 12/01/2022olutasidenib (Rezlidhia, Forma Therapeutics, Inc.)
-
Current as of: 11/18/2022asparaginase erwinia chrysanthemi (recombinant) (Rylaze, Jazz Pharmaceuticals)
-
Current as of: 11/14/2022mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc)
-
Current as of: 11/10/2022tremelimumab (Imjudo, AstraZeneca Pharmaceuticals)
-
Current as of: 11/10/2022brentuximab vedotin (Adcetris, Seagen, Inc)
-
Current as of: 11/08/2022cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc)
-
Current as of: 05/19/2023epcoritamab-bysp (EPKINLY, Genmab US, Inc.)
-
Current as of: 05/31/2023olaparib (LYNPARZA, AstraZeneca Pharmaceuticals LP)
-
Current as of: 06/15/2023glofitamab-gxbm (COLUMVI, Genentech, Inc.)
-
Current as of: 07/31/2023quizartinib (VANFLYTA, Daiichi Sankyo, Inc.)
-
Current as of: 07/31/2023dostarlimab-gxly (JEMPERLI, GlaxoSmithKline)
-
Current as of: 08/02/2023trifluridine and tipiracil (LONSURF, Taiho Oncology, Inc.)
-
Current as of: 08/09/2023pralsetinib (GAVRETO, Genentech, Inc.)
-
Current as of: 09/21/2023talquetamab-tgvs (TALVEY, Janssen Biotech, Inc.)
-
Current as of: 08/11/2023niraparib and abiraterone acetate (AKEEGA, Janssen Biotech, Inc.)
-
Current as of: 09/14/2023elranatamab-bcmm (ELREXFIO, Pfizer, Inc.)
-
Current as of: 09/14/2023melphalan (HEPZATO, Delcath Systems, Inc.)
-
Current as of: 09/14/2023temozolomide (TEMODAR, Merk)
-
Current as of: 06/20/2023talazoparib (TALZENNA, Pfizer, Inc.)
-
Current as of: 11/10/2022Tremelimumab (IMJUDO, AztraZeneca)
-
Current as of: 10/24/2022Tremelimumab (IMJUDO, AztraZeneca)